Combining therapies to improve treatment for non-Hodgkin lymphoma
Official title: Translation of a novel combination therapy approach for non-Hodgkin lymphoma
Funded at Mayo Clinic Rochester · NIH-11043487 · Data updated 2026-11-12
This study is looking at a new treatment for diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma, to find out how to make current therapies work better, and it involves comparing cases in people and dogs to learn more about how to fight this cancer effectively.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $114,223 |
| NIH project number | 3U01CA272257-03S1 |
| Project ID | NIH-11043487 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with diffuse large B-cell lymphoma, particularly those whose cancer has relapsed or is refractory to standard treatments.
✕Less likely to help
Patients with other types of lymphoma or those who are not experiencing relapsed or refractory disease may not benefit from this research.
What this research studies
This research investigates a new combination therapy for diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma, which often has limited treatment options. The study aims to understand why current immunotherapy approaches, like checkpoint inhibitors, are less effective for this type of cancer and to develop better therapeutic strategies. By comparing human and canine cases of lymphoma, researchers hope to gain insights into treatment responses and side effects in a setting that closely mimics human disease. The approach includes using an engineered oncolytic virus to enhance the immune response against the cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with non-Hodgkin lymphoma, improving their chances of recovery.
How similar studies have gone: Previous research has shown promise in using combination therapies and oncolytic viruses for cancer treatment, suggesting potential for success in this novel approach.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Naik, Shruthi — Mayo Clinic Rochester
- Study coordinator: Naik, Shruthi
Related research
Other NIH-funded projects on the same topics.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
Precision targeted radioactive antibody therapy for non-Hodgkin lymphoma
Researchers are developing more precise radioactive antibodies to treat people with CD20-positive non-Hodgkin lymphoma.
-
AI-designed drugs targeting a common lymphoma mutation (MYD88 L265P)
Researchers are using artificial intelligence to create and test new drugs that block a common MYD88 mutation found in many B‑cell non‑Hodgkin lymphomas to help people with these cancers.
-
New combination therapy for non-Hodgkin lymphoma
A virus-based combination treatment aims to boost the immune system to help people and companion dogs with relapsed or treatment-resistant diffuse large B-cell lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.